EBS Valuation

Emergent BioSolutions Inc

Add to Watchlist

Advanced Chart

9.070

+0.23(2.602%)1D

Overview
Forecast
Valuation
Earnings

EBS Relative Valuation

EBS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EBS is overvalued; if below, it's undervalued.

Historical Valuation

Emergent BioSolutions Inc (EBS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.47 is considered Undervalued compared with the five-year average of 14.58. The fair price of Emergent BioSolutions Inc (EBS) is between 130.17 to 158.81 according to relative valuation methord. Compared to the current price of 9.07 USD , Emergent BioSolutions Inc is Undervalued By 93.03%.

Relative Value

Fair Zone

130.17-158.81

Current Price：9.07

93.03%

Undervalued

4.08

Trailing

Forward

7.66

EV/EBITDA

Emergent BioSolutions Inc. (EBS) has a current EV/EBITDA of 7.66. The 5-year average EV/EBITDA is -669.41. The thresholds are as follows: Strongly Undervalued below -6784.72, Undervalued between -6784.72 and -3727.07, Fairly Valued between 2388.25 and -3727.07, Overvalued between 2388.25 and 5445.90, and Strongly Overvalued above 5445.90. The current Forward EV/EBITDA of 7.66 falls within the Historic Trend Line -Fairly Valued range.

8.13

EV/EBIT

Emergent BioSolutions Inc. (EBS) has a current EV/EBIT of 8.13. The 5-year average EV/EBIT is -5.81. The thresholds are as follows: Strongly Undervalued below -78.55, Undervalued between -78.55 and -42.18, Fairly Valued between 30.56 and -42.18, Overvalued between 30.56 and 66.93, and Strongly Overvalued above 66.93. The current Forward EV/EBIT of 8.13 falls within the Historic Trend Line -Fairly Valued range.

0.47

Emergent BioSolutions Inc. (EBS) has a current PS of 0.47. The 5-year average PS is 1.06. The thresholds are as follows: Strongly Undervalued below -0.78, Undervalued between -0.78 and 0.14, Fairly Valued between 1.99 and 0.14, Overvalued between 1.99 and 2.91, and Strongly Overvalued above 2.91. The current Forward PS of 0.47 falls within the Historic Trend Line -Fairly Valued range.

6.79

P/OCF

Emergent BioSolutions Inc. (EBS) has a current P/OCF of 6.79. The 5-year average P/OCF is 6.37. The thresholds are as follows: Strongly Undervalued below -15.18, Undervalued between -15.18 and -4.40, Fairly Valued between 17.14 and -4.40, Overvalued between 17.14 and 27.91, and Strongly Overvalued above 27.91. The current Forward P/OCF of 6.79 falls within the Historic Trend Line -Fairly Valued range.

4.96

P/FCF

Emergent BioSolutions Inc. (EBS) has a current P/FCF of 4.96. The 5-year average P/FCF is 5.26. The thresholds are as follows: Strongly Undervalued below -22.21, Undervalued between -22.21 and -8.48, Fairly Valued between 18.99 and -8.48, Overvalued between 18.99 and 32.73, and Strongly Overvalued above 32.73. The current Forward P/FCF of 4.96 falls within the Historic Trend Line -Fairly Valued range.

Emergent BioSolutions Inc (EBS) has a current Price-to-Book (P/B) ratio of 0.89. Compared to its 3-year average P/B ratio of 0.58 , the current P/B ratio is approximately 53.70% higher. Relative to its 5-year average P/B ratio of 1.30, the current P/B ratio is about -31.95% higher. Emergent BioSolutions Inc (EBS) has a Forward Free Cash Flow (FCF) yield of approximately 32.87%. Compared to its 3-year average FCF yield of -50.35%, the current FCF yield is approximately -165.28% lower. Relative to its 5-year average FCF yield of -27.92% , the current FCF yield is about -217.69% lower.

0.89

P/B

Median3y

0.58

Median5y

1.30

32.87

FCF Yield

Median3y

-50.35

Median5y

-27.92

Competitors Valuation Multiple

The average P/S ratio for EBS's competitors is 28.72, providing a benchmark for relative valuation. Emergent BioSolutions Inc Corp (EBS) exhibits a P/S ratio of 0.47, which is -98.37% above the industry average. Given its robust revenue growth of -44.68%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

EBS.N

Emergent BioSolutions Inc

Eton Pharmaceuticals Inc

Cullinan Therapeutics Inc

63.35

469.64M

LXRX.O

Lexicon Pharmaceuticals Inc

30.29

1652.64%

439.71M

Performance Decomposition

Market capitalization of EBS increased by 9.15% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 1.42 to 3.50.

The secondary factor is the Revenue Growth, contributed -44.68%to the performance.

Overall, the performance of EBS in the past 1 year is driven by P/E Change. Which is more unsustainable.

-44.68%

254.70M → 140.90M

Revenue Growth

-92.33%

-111.15 → -8.52

Margin Expansion

146.16%

1.42 → 3.50

P/E Change

9.15%